Hikma Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	3,349	3,127	2,875	2,517	2,553
Revenue Growth (YoY)	7.10%	8.77%	14.22%	-1.41%	9.06%
Cost of Revenue	1,892	1,708	1,468	1,252	1,252
Gross Profit	1,457	1,419	1,407	1,265	1,301
Selling, General & Admin	666	660	632	601	561
Research & Development	151	141	149	144	143
Other Operating Expenses	-8	4	1	22	36
Operating Expenses	809	805	782	767	740
Operating Income	648	614	625	498	561
Interest Expense	-85	-75	-73	-59	-43
Interest & Investment Income	6	8	7	3	1
Earnings From Equity Investments	-	1	-	-	1
Currency Exchange Gain (Loss)	-11	-21	-9	-7	-
Other Non Operating Income (Expenses)	-12	-13	-14	-11	-13
EBT Excluding Unusual Items	546	514	536	424	507
Merger & Restructuring Charges	-21	-15	-	-41	-
Gain (Loss) on Sale of Investments	1	1	2	-2	-
Gain (Loss) on Sale of Assets	-	-	-	12	-1
Asset Writedown	-26	29	-85	-182	22
Legal Settlements	-72	-	-129	-	-
Other Unusual Items	77	-74	-43	22	16
Pretax Income	519	455	281	233	544
Income Tax Expense	112	93	89	42	124
Earnings From Continuing Operations	407	362	192	191	420
Minority Interest in Earnings	-5	-3	-2	-3	1
Net Income	402	359	190	188	421
Net Income to Common	402	359	190	188	421
Net Income Growth	11.98%	88.95%	1.06%	-55.34%	-2.32%
Shares Outstanding (Basic)	221	221	221	224	231
Shares Outstanding (Diluted)	223	223	222	225	233
Shares Change (YoY)	-0.36%	0.51%	-1.13%	-3.47%	-2.10%
EPS (Basic)	1.82	1.62	0.86	0.84	1.82
EPS (Diluted)	1.81	1.61	0.85	0.84	1.81
EPS Growth	12.42%	89.41%	1.19%	-53.51%	-0.22%
Free Cash Flow	239	399	439	392	493
Free Cash Flow Per Share	1.07	1.78	1.97	1.74	2.12
Dividend Per Share	0.840	0.800	0.720	0.560	0.540
Dividend Growth	5.00%	11.11%	28.57%	3.70%	8.00%
Gross Margin	43.51%	45.38%	48.94%	50.26%	50.96%
Operating Margin	19.35%	19.63%	21.74%	19.79%	21.97%
Profit Margin	12.00%	11.48%	6.61%	7.47%	16.49%
Free Cash Flow Margin	7.14%	12.76%	15.27%	15.57%	19.31%
EBITDA	842	793	797	670	718
EBITDA Margin	25.14%	25.36%	27.72%	26.62%	28.12%
D&A For EBITDA	194	179	172	172	157
EBIT	648	614	625	498	561
EBIT Margin	19.35%	19.63%	21.74%	19.79%	21.97%
Effective Tax Rate	21.58%	20.44%	31.67%	18.03%	22.79%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.